The German landscape for introduction of new technologies and drugs is changing dramatic. For drugs, the introduction of the Amnog process has been a drastic change. Now the medical devices are undergoing a similar drastic change, where new medical technologies coming to market through the innovation funding pathway have to go through a benefit assessment.